钇90微球放射栓塞治疗肝脏恶性肿瘤研究的全球现状与发展趋势：一项文献计量学分析

摘要/Abstract

摘要： 目的：通过文献计量学分析探讨钇90微球放射栓塞治疗肝脏恶性肿瘤研究的全球现状与发展趋势。
方法：以Web of Science数据库中1991—2021年收录的钇90微球放射栓塞治疗肝脏恶性肿瘤相关文献为对象,应用VOS viewer软件对国家、机构、作者、期刊、关键词进行文献计量学分析,并绘制可视化的合作关系网络图谱。
结果：根据检索策略和筛选标准,共989篇钇90微球放射栓塞治疗肝脏恶性肿瘤的相关文献纳入本研究,来自47个国家1 055个机构4 406名研究人员参与其中。该领域发表文献数量整体呈明显上升趋势,2021年达到峰值。美国在国家合作和发表文献数量上占据主导地位。在机构中,美国的西北大学发表文献数量最多,西班牙的纳瓦拉大学和美国的华盛顿大学次之。发表文献数量和总被引频次前3位的作者分别是Salem R、Lewandowski RJ和Mulcahy MF。Journal of Vascular and Interventional Radiology等期刊在推动该领域发展中发挥了重要作用。出现频次最高的10个关键词是放射栓塞、肝细胞癌、钇90、钇90微球、生存、癌症、肝转移、微球、选择性内放射治疗和内放射治疗。
结论：目前钇90微球放射栓塞治疗肝脏恶性肿瘤是重要研究热点之一,中国的研究人员不仅需要关注该领域的前沿研究,还应积极开展多中心临床研究项目。

关键词: 钇90微球, 放射栓塞, 选择性内放射治疗, 肝脏恶性肿瘤, 文献计量学分析

Abstract: Objective:To investigate the global status and development trends of radioembolization for liver cancer with yttrium-90 through bibliometric analysis.
Method:All available data of the articles concerning radioembolization for liver cancer with yttrium-90, based on Web of Science database from 1991 to 2021, were analyzed with bibliometric analysis for creating visual knowledge maps of the countries, institutions, authors, journals and keywords by VOS viewer.
Result:According to the search strategy and screening criteria, a total of 989 articles related to radioembolization for liver cancer with yttrium-90 were included in this study, involving 4 406 researchers from 1 055 institutions in 47 countries. The overall number of annual and cumulative publications significantly showed an upward trend, reaching a peak in 2021. United States dominated in national cooperation and number of articles. The top three institutions of total publications were Northwestern University, University of Navarra and Washington University. The top three authors of total publications and citations were Salem R, Lewandowski RJ and Mulcahy MF. Journal of Vascular and Interventional Radiology and other journals have played a vital role in promoting the development of this field. The top 10 keywords with occurrence frequency were radioembolization, hepatocellular carcinoma, yttrium-90, Y-90 microspheres, survival, cancer, liver metastases, microspheres, selective internal radiation therapy and internal radiation therapy.
Conclusion:Radioembolization for liver cancer with yttrium-90 is one of the important research hotspots of liver cancer. Chinese researchers should not only pay attention to the frontier research in this field, but also actively carry out multicenter clinical research projects.

Key words: Yttrium-90, Radioembolization, Selective internal radiation therapy, Liver cancer, Bibliometric analysis

唐凡, 骆银根, 欧爱鑫, 徐昊冉, 李肖. 钇90微球放射栓塞治疗肝脏恶性肿瘤研究的全球现状与发展趋势：一项文献计量学分析[J]. 肝癌电子杂志, 2023, 10(3): 38-47.

Tang Fan, Luo Yingen, Ou Aixin, Xu Haoran, Li Xiao. The global status and development trends of radioembolization for liver cancer with yttrium-90: a bibliometric analysis[J]. Electronic Journal of Liver Tumor, 2023, 10(3): 38-47.

参考文献

[1] SUNG H, FERLAY J, SIEGEL R L, et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] 中国临床肿瘤学会核医学专家委员会, 北京市核医学质量控制和改进中心. 钇-90(⁹⁰Y)微球选择性内放射治疗原发性和转移性肝癌的中国专家共识[J]. 中华肝脏病杂志, 2021, 29(7): 648-658.
[3] LEWANDOWSKI R J, GESCHWIND J F, LIAPI E, et al.Transcatheter intraarterial therapies: rationale and overview[J]. Radiology, 2011, 259(3): 641-657.
[4] SALEM R, GABR A, RIAZ A, et al.Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience[J]. Hepatology, 2018, 68(4): 1429-1440.
[5] MIOT H A, IANHEZ M, RAMOS P M.Trends in bibliometric indexes of the main dermatology journals (2009 to 2019)[J]. J Am Acad Dermatol, 2021, 85(3): 782-783.
[6] YU Q, TAN S, REN Y, et al.Bibliometric analysis of the 100 most-cited articles in the field of hepatology[J]. Gastroenterol Hepatol, 2020, 43(7): 349-357.
[7] SALEM R, LEWANDOWSKI R J, MULCAHY M F, et al.Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes[J]. Gastroenterology, 2010, 138(1): 52-64.
[8] WEBER M, LAM M, CHIESA C, et al.EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds[J]. Eur J Nucl Med Mol Imaging, 2022, 49(5): 1682-1699.
[9] O'DOHERTY J, SCUFFHAM J, HINTON P. The importance of scatter correction for the assessment of lung shunting prior to yttrium-90 radioembolization therapy[J]. Nucl Med Commun, 2011, 32(7): 628-634.
[10] BILBAO J I, GARRASTACHU P, HERRÁIZ M J, et al. Safety and efficacy assessment of flow redistribution by occlusion of intrahepatic vessels prior to radioembolization in the treatment of liver tumors[J]. Cardiovasc Intervent Radiol, 2010, 33(3): 523-531.
[11] CAMACHO J C, MONCAYO V, KOKABI N, et al.90Y Radioembolization: Multimodality Imaging Pattern Approach with Angiographic Correlation for Optimized Target Therapy Delivery[J]. Radiographics, 2015, 35(5): 1602-1618.
[12] TAFTI B A, PADIA S A.Dosimetry of Y-90 Microspheres Utilizing Tc-99m SPECT and Y-90 PET[J]. Semin Nucl Med, 2019, 49(3): 211-217.
[13] GULEC S A, MESOLORAS G, STABIN M.Dosimetric techniques in ⁹⁰Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations[J]. J Nucl Med, 2006, 47(7): 1209-1211.
[14] RIAZ A, GATES V L, ATASSI B, et al.Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization[J]. Int J Radiat Oncol Biol Phys, 2011, 79(1): 163-171.
[15] KULIK L M, CARR B I, MULCAHY M F, et al.Safety and efficacy of ⁹⁰Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis[J]. Hepatology, 2008, 47(1): 71-81.
[16] SOMMA F, STOIA V, SERRA N, et al.Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival[J]. PLoS One, 2019, 14(5): e0216935.
[17] VOUCHE M, HABIB A, WARD T J, et al.Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy[J]. Hepatology, 2014, 60(1): 192-201.
[18] LEWANDOWSKI R J, KULIK L M, RIAZ A, et al.A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization[J]. Am J Transplant, 2009, 9(8): 1920-1928.
[19] FERNÁNDEZ-ROS N, SILVA N, BILBAO J I, et al. Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension[J]. HPB (Oxford), 2014, 16(3): 243-249.
[20] SALEM R, GORDON A C, MOULI S, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared with Chemoembolization in Patients with Hepatocellular Carcinoma[J]. Gastroenterology, 2016, 151(6): 1155-1163.e2.
[21] VILGRAIN V, PEREIRA H, ASSENAT E, et al.Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial[J]. Lancet Oncol, 2017, 18(12): 1624-1636.
[22] CHOW P K H, GANDHI M, TAN S B, et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients with Hepatocellular Carcinoma[J]. J Clin Oncol, 2018, 36(19): 1913-1921.
[23] ALI R, RIAZ A, GABR A, et al.Clinical outcomes of Y90 radioembolization for recurrent hepatocellular carcinoma following curative resection[J]. Eur J Nucl Med Mol Imaging, 2017, 44(13): 2195-2202.
[24] IBRAHIM S M, MULCAHY M F, LEWANDOWSKI R J, et al.Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study[J]. Cancer, 2008, 113(8): 2119-2128.
[25] HOFFMANN R T, PAPROTTKA P M, SCHÖN A, et al. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival[J]. Cardiovasc Intervent Radiol, 2012, 35(1): 105-116.
[26] MOSCONI C, GRAMENZI A, ASCANIO S, et al.Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study[J]. Br J Cancer, 2016, 115(3): 297-302.
[27] MULCAHY M F, MAHVASH A, PRACHT M, et al.Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, PhaseⅢ Trial[J]. J Clin Oncol, 2021, 39(35): 3897-3907.
[28] WASAN H S, GIBBS P, SHARMA N K, et al.First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials[J]. Lancet Oncol, 2017, 18(9): 1159-1171.
[29] CHENG B, SETHI I, DAVISSON N, et al.Yttrium-90 dosimetry and implications on tumour response and survival after radioembolisation of chemo-refractory hepatic metastases from breast cancer[J]. Nucl Med Commun, 2021, 42(4): 402-409.
[30] TSANG E S, LOREE J M, DAVIES J M, et al.Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases[J]. Can J Gastroenterol Hepatol, 2020: 5104082.
[31] 颜志平, 林贵, 赵惠扬. 90钇玻璃微球内放射治疗原发性肝癌的初步临床应用[J]. 中华放射学杂志, 1994, (1): 55-57.
[32] ZU Q, SCHENNING R C, JAHANGIRI Y, et al.Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?[J]. Cardiovasc Intervent Radiol, 2020, 43(5): 721-731.
[33] JIA Z, PAZ-FUMAGALLI R, FREY G T, et al.Prognostic factors in patients treated with transarterial radioembolization for unresectable and chemorefractory colorectal cancer with liver metastases[J]. Expert Rev Gastroenterol Hepatol, 2019, 13(9): 899-905.
[34] 牛惠敏, 王志恒, 高石鑫, 等. 钇90放射性微球在肝脏恶性肿瘤中的应用及进展[J/CD]. 肝癌电子杂志, 2021, 8(4): 36-40.
[35] 郑致远. 钇90放射性微球治疗肝脏恶性肿瘤的应用进展[J]. 复旦学报(医学版), 2020, 47(4): 622-627.